Plasminogen activator inhibitor type I may contribute to transient, non-specific changes in immunity in the subacute phase of murine tuberculosis

Microbes and Infection

Volumn 14, Issue 9, 2012, Pages 748-755

  Kager, Liesbeth M ^a   Van der Windt, Gerritje J W ^a   Wieland, Catharina W ^a   Florquin, Sandrine ^a   Veer, Cornelis van 't ^a   Van der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Fibrinolysis; Immunity; Inflammation; Plasminogen activator inhibitor type 1 (PAI 1); Tuberculosis

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUBERCULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNITY; LYMPHOCYTE; MACROPHAGE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SPLEEN CELL; TUBERCULOSIS; UPREGULATION;

ANIMALS; BACTERIAL LOAD; CYTOKINES; DISEASE MODELS, ANIMAL; LUNG; LYMPHOCYTES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYCOBACTERIUM TUBERCULOSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUBERCULOSIS;

BACTERIA (MICROORGANISMS); MURINAE; MUS; MYCOBACTERIUM TUBERCULOSIS;

EID: 84863096201     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2012.03.001     Document Type: Article

References (32)

1. Arndt P.G., Young S.K., Worthen G.S. Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway. J. Immunol. 2005, 175:4049-4059.
2. Choi G., Schultz M.J., van Till J.W., Bresser P., van der Zee J.S., Boermeester M.A., Levi M., van der Poll T. Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur. Respir. J. 2004, 24:786-789.
3. Chung C.L., Chen C.H., Sheu J.R., Chen Y.C., Chang S.C. Proinflammatory cytokines, transforming growth factor-beta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates. Chest 2005, 128:690-697.
4. Cooper A.M., Khader S.A. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol. Rev. 2008, 226:191-204.
5. Delvaeye M., Conway E.M. Coagulation and innate immune responses: can we view them separately?. Blood 2009, 114:2367-2374.
6. Eitzman D.T., McCoy R.D., Zheng X., Fay W.P., Shen T., Ginsburg D., Simon R.H. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest. 1996, 97:232-237.
7. Gandhi N.R., Nunn P., Dheda K., Schaaf H.S., Zignol M., van S.D., Jensen P., Bayona J. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375:1830-1843.
8. Gunther A., Mosavi P., Heinemann S., Ruppert C., Muth H., Markart P., Grimminger F., Walmrath D., Temmesfeld-Wollbruck B., Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 2000, 161:454-462.
9. Hua C.C., Chang L.C., Chen Y.C., Chang S.C. Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions. Chest 1999, 116:1292-1296.
10. Juffermans N.P., Florquin S., Camoglio L., Verbon A., Kolk A.H., Speelman P., van Deventer S.J., van Der P.T. Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. J. Infect. Dis. 2000, 182:902-908.
11. Kaufmann S.H. How can immunology contribute to the control of tuberculosis?. Nat. Rev. Immunol. 2001, 1:20-30.
12. Kwak S.H., Wang X.Q., He Q., Fang W.F., Mitra S., Bdeir K., Ploplis V.A., Xu Z., Idell S., Cines D., Abraham E. Plasminogen activator inhibitor-1 potentiates LPS-induced neutrophil activation through a JNK-mediated pathway. Thromb. Haemost. 2006, 95:829-835.
13. Leemans J.C., Florquin S., Heikens M., Pals S.T., van der Neut R., van der Poll T. CD44 is a macrophage binding site for Mycobacterium tuberculosis that mediates macrophage recruitment and protective immunity against tuberculosis. J. Clin. Invest. 2003, 111:681-689.
14. Lijnen H.R. Pleiotropic functions of plasminogen activator inhibitor-1. J. Thromb. Haemost. 2005, 3:35-45.
15. Lim J.H., Stirling B., Derry J., Koga T., Jono H., Woo C.H., Xu H., Bourne P., Ha U.H., Ishinaga H., Xu H., Andalibi A., Feng X.H., Zhu H., Huang Y., Zhang W., Weng X., Yan C., Yin Z., Briles D.E., Davis R.J., Flavell R.A., Li J.D. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 2007, 27:349-360.
16. Maartens G., Wilkinson R.J. Tuberculosis. Lancet 2007, 370:2030-2043.
17. Marshall L.J., Ramdin L.S., Brooks T., DPhil P.C., Shute J.K. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J. Immunol. 2003, 171:2057-2065.
18. Park Y.J., Liu G., Lorne E.F., Zhao X., Wang J., Tsuruta Y., Zmijewski J., Abraham E. PAI-1 inhibits neutrophil efferocytosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11784-11789.
19. Poggi M., Paulmyer-Lacroix O., Verdier M., Peiretti F., Bastelica D., Boucraut J., Lijnen H.R., Juhan-Vague I., Alessi M.C. Chronic plasminogen activator inhibitor-1 (PAI-1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung. J. Thromb. Haemost. 2007, 5:2467-2475.
20. Renckens R., Pater J.M., van der Poll T. Plasminogen activator inhibitor type-1-deficient mice have an enhanced IFN-gamma response to lipopolysaccharide and staphylococcal enterotoxin B. J. Immunol. 2006, 177:8171-8176.
21. Renckens R., Roelofs J.J., Bonta P.I., Florquin S., de Vries C.J., Levi M., Carmeliet P., van't Veer C., van der Poll T. Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia. Blood 2007, 109:1593-1601.
22. Robson S.C., White N.W., Aronson I., Woollgar R., Goodman H., Jacobs P. Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. Br. J. Haematol. 1996, 93:943-949.
23. Russell D.G. Who puts the tubercle in tuberculosis?. Nat. Rev. Microbiol. 2007, 5:39-47.
24. Sato J., Schorey J., Ploplis V.A., Haalboom E., Krahule L., Castellino F.J. The fibrinolytic system in dissemination and matrix protein deposition during a mycobacterium infection. Am. J. Pathol. 2003, 163:517-531.
25. Schultz M.J., Millo J., Levi M., Hack C.E., Weverling G.J., Garrard C.S., van der Poll T. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004, 59:130-135.
26. Senoo T., Hattori N., Tanimoto T., Furonaka M., Ishikawa N., Fujitaka K., Haruta Y., Murai H., Yokoyama A., Kohno N. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 2010, 65:334-340.
27. Turken O., Kunter E., Sezer M., Solmazgul E., Cerrahoglu K., Bozkanat E., Ozturk A., Ilvan A. Hemostatic changes in active pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 2002, 6:927-932.
28. Weijer S., Wieland C.W., Florquin S., van der Poll T. A thrombomodulin mutation that impairs activated protein C generation results in uncontrolled lung inflammation during murine tuberculosis. Blood 2005, 106:2761-2768.
29. WHO Global tuberculosis control: WHO report 2010 2010, WHO/HTM/TB/2010.7, Ref Type: Generic.
30. Wieland C.W., Knapp S., Florquin S., de Vos A.F., Takeda K., Akira S., Golenbock D.T., Verbon A., van der Poll T. Non-mannose-capped lipoarabinomannan induces lung inflammation via toll-like receptor 2. Am. J. Respir. Crit. Care Med. 2004, 170:1367-1374.
31. Wieland C.W., van der Windt G.J., Florquin S., McKenzie A.N., van der Poll T. ST2 deficient mice display a normal host defense against pulmonary infection with Mycobacterium tuberculosis. Microbes Infect. 2009, 11:524-530.
32. Wieland C.W., van der Windt G.J., Wiersinga W.J., Florquin S., van der Poll T. CD14 contributes to pulmonary inflammation and mortality during murine tuberculosis. Immunology 2008, 125:272-279.